Sign in
Retrospective Real-World Analysis of Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration Followed for 3 Years
Ehsan Rahimy, MD
Annual Meeting Talks
2022
Baseline Factors Associated With 1-Year Outcomes in Phase III Comparison of SB11 (Approved Ranibizumab Biosimilar) With Reference Ranibizumab in nAMD
Neil M. Bressler, MD
Episode 131: Journal Club on Follow-up for AMD and PDR Patients, Phase II and III Clinical Trials, Ophthalmology Chairs in the U.S. with Dr. M. Ali Khan
Jayanth Sridhar, MD
Member Podcasts
2018
Category: AMD-Non-Neovascular